^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

COMPANY:
Guardant Health

i
Other names: Guardant Health | Guardant Health, Inc.
Related tests:
Evidence

News

15d
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting (Businesswire)
"Guardant Health, Inc...announced it will present data from nine studies highlighting advances in methylation-based epigenomic analysis for precision oncology at the 2024 American Association for Cancer Research (AACR) Annual Meeting, April 5-10 in San Diego. Multiple poster sessions will report on the utility of using the Guardant Infinity platform across the continuum of cancer care, ranging from predictive histologic subtyping of tumors to cardiac adverse event prediction. Data will also be presented demonstrating strong performance of Guardant Reveal for minimal residual disease (MRD) detection in breast cancer, allowing quantification of ctDNA even in early-stage disease without the need for a tissue specimen."
Clinical data • Clinical
|
Guardant360® CDx • GuardantOMNI • GuardantINFINITY™ • GuardantREVEAL
20d
Royal Marsden and Guardant Health partnership provides state-of-the-art blood test to benefit lung cancer patients in expanded NHS study (Guardant Health Press Release)
"The NHS England study – conducted in partnership with The Royal Marsden and Guardant Health – has already enabled over 2000 patients with suspected advanced lung cancer to have a ctDNA blood test before or at the same time that diagnostic biopsies are taken. Analysis of data from Guardant Health’s liquid biopsy testing shows that time to diagnosis for patients with advanced lung cancer in the UK can be slashed by three weeks, allowing faster access to personalised therapies that target the identified mutations."
Licensing / partnership
1m
Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine (Businesswire)
P=Obs | N=40,000 | ECLIPSE (NCT04136002) | Sponsor: Guardant Health, Inc. | "Guardant Health...announced that results from the ECLIPSE study showing the effectiveness of its Shield blood test for detecting colorectal cancer (CRC) in average-risk adults will be published in the March 14 issue of The New England Journal of Medicine....Highlights of the study results to be published in The New England Journal of Medicine show that Shield demonstrated: 83% sensitivity in detecting individuals with CRC; 88% sensitivity in detecting pathology-confirmed Stages I-III; Sensitivity by stage of: 65% for pathology-confirmed Stage I; 55% for clinical Stage I; 100% for Stage II; 100% for Stage III; 100% for Stage IV. These results are on par with the performance of other guideline-recommended non-invasive screening modalities, where overall sensitivity in detecting colorectal cancer ranges from 74% to 92%."
Observational data
|
GUARDANT SHIELD
3ms
Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence (Businesswire)
"Guardant Health, Inc...will present interim data from the COSMOS study supporting the use of Guardant Reveal to predict disease recurrence in patients with early-stage colon cancer at the ASCO 2024 Gastrointestinal Cancers Symposium, January 18-20 in San Francisco....Interim data to be shared at ASCO GI suggest the test is both highly specific (low false positives) and predictive for recurrence, without dependence on a tissue sample....Guardant and its research partners will also present multiple posters at the symposium highlighting the application of Guardant technology in blood-based screening and in identifying potentially targetable mutations in GI cancers, including predictive markers for treatment resistance."
P2/3 data
|
Guardant360® CDx • GUARDANT SHIELD • GuardantREVEAL
3ms
Guardant Health and Hikma partner to offer cancer screening and comprehensive genomic profiling tests in the Middle East and North Africa (Guardant Health Press Release)
"Guardant Health, Inc...and Hikma Pharmaceuticals PLC...announced an agreement to promote Guardant Health’s portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumor mutation profiling across all solid cancers in countries across the Middle East and North Africa (MENA)...The tests offered include Shield™ for cancer screening and early detection, Guardant Reveal™ for minimal residual disease detection and recurrence monitoring, and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers."
Licensing / partnership
|
Guardant360® CDx • Guardant360 TissueNext™ • GUARDANT SHIELD • GuardantREVEAL
4ms
Guardant Health announces tentative date of FDA Advisory Panel review of Shield™ blood test (Guardant Health Press Release)
"Guardant Health, Inc...announced that the U.S. Food and Drug Administration’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is tentatively scheduled to review the premarket approval application (PMA) for the company’s Shield™ blood test to screen for colorectal cancer on March 28, 2024. The date and details of the meeting are subject to confirmation by the FDA and publication in the Federal Register."
FDA event
|
GUARDANT SHIELD
5ms
Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities (Businesswire)
"Cancer Research UK, one of the world’s largest charitable funders of cancer research, its innovation unit, Cancer Research Horizons, and Guardant Health, Inc...today announced a collaboration to explore the sharing of technologies, data, and insights to advance the development and precision of cancer detection and treatment. The agreement will enable the parties to discuss opportunities for collaboration to support the charity’s research and clinical development activities, focusing primarily on its clinical trials run by its Centre for Drug Development."
Licensing / partnership
5ms
Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection (Guardant Health Press Release)
"Guardant Health, Inc...will present data showing the utility of liquid biopsy tests in the management of breast cancer patients at the San Antonio Breast Cancer Symposium, December 5-9 in San Antonio, Texas. Highlights of the eight poster presentations include the use of blood-based testing to identify actionable biomarkers and predict therapy response in advanced breast cancer, and to detect residual disease and predict recurrence in patients with early-stage breast cancer."
Clinical data
|
Guardant360® CDx • GuardantOMNI • GuardantREVEAL
5ms
Guardant Health to appeal Federal District Court verdict (Guardant Health Press Release)
"Guardant Health, Inc...announced it intends to appeal yesterday’s verdict in the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington...Guardant remains confident that it did not infringe the asserted patents, and the company expects to file additional motions with the U.S. District Court for the District of Delaware and appeal to the U.S. Court of Appeals for the Federal Circuit."
Corporate lawsuit • Patent
5ms
Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea (PRNewswire)
"Guardant Health, Inc...announced that it has launched its blood-based colorectal cancer screening test, Shield, in collaboration with Samsung Medical Center in South Korea. Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and the third-leading cause of cancer-related deaths in South Korea. Guardant Health's Shield test, which can be used for regular CRC screening in eligible individuals, is an innovative test that can detect cancer in its early stages by analysing circulating tumour DNA (ctDNA), which is produced when tumours shed small pieces of their genetic material into the bloodstream. In the pivotal ECLIPSE study, which enrolled over 20,000 patients, the Shield test achieved 83% sensitivity for the detection of colorectal cancer in average-risk adults in the U.S., with specificity of 90%."
Launch non-US
|
GUARDANT SHIELD
6ms
Zydus Lifesciences to co-promote Guardant Health biopsy tests in India and Nepal (The Hindu Business Line)
"Zydus Lifesciences and Guardant Health have agreed to jointly promote the Guardant360 portfolio of liquid and tissue biopsy tests across India and Nepal...The tests to be promoted include the Guardant360 and Guardant360 TissueNext tests for genomic profiling and the Guardant360 Response test for monitoring response to treatment..."
Licensing / partnership
|
Guardant360® CDx • Guardant360 TissueNext™ • Guardant360 Response™
6ms
Guardant Health, Flatiron Health announce integration of Guardant genomic profiling tests into OncoEMR® platform (Guardant Health Press Release)
"Guardant Health, Inc...announced an initiative to integrate Guardant’s comprehensive genomic profiling tests within Flatiron’s OncoEMR®, a leading cloud-based electronic medical record (EMR) tool...Users can easily submit Guardant Health test orders, track real-time status updates, and receive the test results directly in the patient record, via the Molecular Profiling Integration on the OncoEMR platform."
Licensing / partnership
6ms
First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer (Businesswire)
P2 | N=140 | PEGASUS (NCT04259944) | "Guardant Health, Inc...announced that initial results from the PEGASUS trial suggest liquid biopsy may be used in post-surgical clinical management to reduce unnecessary toxicity from chemotherapy and improve the response to standard chemotherapy regimens in patients with stage III or high-risk stage II colon cancer...Initial results show that 34% of patients with a positive liquid biopsy result after surgery had the cancer return, while only 10% of patients with a negative result experienced a relapse. Approximately 40% of patients converted from ctDNA-positive to ctDNA-negative after treatment, suggesting treatment efficacy of chemotherapy for some patients."
P2 data
|
GuardantREVEAL
6ms
Guardant Health, EDX Medical Ink UK, Nordic distribution deal (Genomeweb)
"Digital diagnostics company EDX Medical Group announced...that it will distribute two of Guardant Health's cancer liquid biopsy tests in the UK and the Nordic countries...EDX Medical will distribute the Guardant360 CDx advanced cancer genomic test and the Guardant Reveal test for residual disease and recurrence detection in early-stage cancer to the UK private healthcare sector...It will also distribute Guardant360 CDx to the public and private sectors in Sweden, Denmark, Norway, Finland, and Iceland."
Licensing / partnership
|
Guardant360® CDx • GuardantREVEAL
7ms
Adicon offers liquid biopsy tests from Guardant Health to accelerate development of new cancer therapies in China (Guardant Health Press Release)
"Adicon Holdings Limited...announced that it now offers liquid biopsy tests from Guardant Health...to advance clinical research and the development of new cancer therapies in China. The blood-based tests provide biopharmaceutical companies with access to comprehensive genomic profiling (CGP), also known as tumour mutation profiling, in patients with advanced solid cancers to support investigational drug studies."
Licensing / partnership • Clinical
7ms
Guardant Health receives coverage for Guardant Reveal™ from Geisinger Health Plan (Guardant Health Press Release)
"Guardant Health, Inc...announced...that Geisinger Health Plan now offers coverage for the Guardant Reveal™ minimal residual disease (MRD) test. Guardant Reveal is a blood test that detects circulating tumor DNA (ctDNA) in blood after treatment, including surgery, to help oncologists identify cancer patients with residual or recurring disease who may benefit most from adjuvant therapy or surveillance...This policy decision adds to the payor coverage of Guardant Reveal, which received Medicare coverage in August 2022 and additional commercial payor coverage in July 2023."
Medicare • Reimbursement
|
GuardantREVEAL
8ms
Guardant Health Receives Regulatory Approval in Japan for Guardant360 CDx as Companion Diagnostic to ENHERTU for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations (Businesswire)
"Guardant Health...announced the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Guardant360® CDx liquid biopsy test as a companion diagnostic to select patients with unresectable (inoperable) advanced or recurrent non-small cell lung cancer (NSCLC) with HER2 (ERBB2) mutations that has progressed after chemotherapy for treatment with ENHERTU® (trastuzumab deruxtecan)....The approval for use of the test as a companion diagnostic with ENHERTU in Japan is an expansion of the approval received from the U.S. Food and Drug Administration (FDA) for the same indication in August 2022."
Japanese regulatory
|
Guardant360® CDx
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
8ms
Guardant Health provides update on COBRA study, restates confidence in MRD test (Guardant Health Press Release)
"Guardant Health, Inc...issued the following statement about the closure of COBRA, a minimum residual disease (MRD) study...We agree with the decision, based on the recent planned interim analysis, to close the COBRA study to new enrollees..."
Trial status • Enrollment closed
9ms
Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research (Guardant Health Press Release)
"Guardant Health, Inc...announced an agreement with Illumina Inc...that resolves their pending litigation and promotes a shared resolution to advance the companies’ long-term, commercial partnership...The companies have also extended their long-standing commercial relationship by agreeing to collaborate on the sharing of specimen samples to advance cancer research, and by entering into a new long-term purchase and supply commitment."
Corporate lawsuit • Licensing / partnership
9ms
Guardant Health receives first commercial payor coverage for Guardant Reveal™ test from Blue Cross and Blue Shield of Louisiana (Guardant Health Press Release)
"Guardant Health, Inc...announced...that Blue Cross and Blue Shield of Louisiana now offers coverage for the Guardant Reveal™ molecular residual disease (MRD) test. Guardant Reveal is a blood test that detects circulating tumor DNA (ctDNA) in blood after treatment, including surgery, to help oncologists identify cancer patients with residual or recurring disease who may benefit most from adjuvant therapy or surveillance. It was the first blood-only liquid biopsy test commercially available for MRD testing."
Reimbursement
|
GuardantREVEAL
10ms
Guardant Health announces reimbursement approval of Guardant360 CDx liquid biopsy test in Japan (Businesswire)
"Guardant Health, Inc...announced today that it has been informed it will receive national reimbursement approval from the Japanese Ministry of Health, Labor and Welfare (MHLW), effective July 24, 2023, for its Guardant360® CDx liquid biopsy test for comprehensive genomic profiling (CGP) for patients with advanced or metastatic solid tumor cancers. This announcement follows the regulatory approval of the Guardant360 CDx test by the MHLW in March 2022."
Reimbursement
|
Guardant360® CDx
11ms
Guardant Health Receives Regulatory Approval from Singapore’s Health Sciences Authority for Guardant360 CDx blood test for patients with advanced solid cancers (PRNewswire.co.uk)
"Guardant Health...announced today that Singapore's Health Sciences Authority (HSA) has granted regulatory approval of Guardant360® CDx, a liquid biopsy test for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with advanced solid cancers. The Guardant360 CDx test was also approved as a companion diagnostic to identify patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with TAGRISSO® (osimertinib). Guardant360 CDx is the first blood test to be approved by Singapore's HSA for comprehensive genomic profiling for all solid tumors."
Non-US regulatory
|
Guardant360® CDx
|
Tagrisso (osimertinib)
11ms
Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting (Businesswire)
"Guardant Health, Inc...announced today that the company and its research collaborators will present data from 17 studies that highlight the contribution of Guardant blood tests and real-world data to advances in precision oncology and cancer screening at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting, June 2-6 in Chicago....Guardant Health will present a session highlighting the performance of the Guardant Infinity platform in the detection of homologous recombination deficiency (HRD) status in patients with breast cancer....Guardant Health collaborators will present a session on the ESR1 mutational landscape and the impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer."
Clinical data
|
Guardant360® CDx • GUARDANT SHIELD • GuardantINFINITY™
11ms
Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360 Blood Test for Comprehensive Genomic Profiling (Businesswire)
"Guardant Health, Inc...announced today that it has received new commercial health plan coverage for the Guardant360 liquid biopsy test from Anthem Blue Cross and Blue Shield, Aetna and Humana. With this additional coverage, Guardant360 CDx/Guardant360 is now covered for comprehensive genomic profiling by all major U.S. commercial health insurers....The Guardant360 test received coverage under Anthem Blue Cross and Blue Shield commercial health insurance policies for complete genomic profiling of any solid tumor to identify actionable biomarkers to inform therapy selection."
Reimbursement
|
Guardant360® CDx
11ms
Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test (Guardant Health Press Release)
"Guardant Health, Inc...presented additional data from the ECLIPSE study at 2023 Digestive Disease Week (DDW) titled, 'Clinical Validation of a Cell-Free DNA Blood-Based Test for Colorectal Cancer in an Average Risk Population' (Abstract #913e) showcasing the performance of its blood-based technology to accurately detect early-stage colorectal cancer (CRC)...Shield™ blood test achieved overall 83% sensitivity and 90% specificity and demonstrated early-stage detection in range with other guideline-recommended non-invasive CRC screening modalities"
Clinical data
|
GUARDANT SHIELD
12ms
Guardant Health Announces ECLIPSE Study Update Call on May 9, 2023 (Businesswire)
"Guardant Health, Inc...announced it will report additional data from its pivotal ECLIPSE study at Digestive Disease Week (DDW) on Tuesday, May 9, 2023. The company will host a webcast and conference call with primary investigators of the study and other cancer screening experts beginning at 11:00 a.m. ET / 8:00 a.m. PT."
Observational data
12ms
Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response (Businesswire)
"Guardant Health, Inc...and the Parker Institute for Cancer Immunotherapy...announced a research collaboration agreement to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across more than 14 different types of cancer. Under the agreement, Guardant Health will analyze patient blood samples from PICI’s RADIOHEAD (Resistance Drivers for Immuno-Oncology Patients Interrogated by Harmonized Molecular Datasets) prospective study of 1,200 individuals on standard-of-care immune checkpoint inhibitor (ICI) treatment regimens in community hospitals....Guardant Health and PICI intend to begin publishing data generated by the study later in 2023."
Licensing / partnership • Clinical data
|
GuardantINFINITY™
12ms
Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer (Businesswire)
"Guardant Health, Inc...is pleased to announce that it will present data from two studies highlighting the performance of its blood-based screening technology to detect early-stage colorectal cancer (CRC), including the acceptance of the ECLIPSE study as a late-breaking abstract, at Digestive Disease Week (DDW) taking place in Chicago, Illinois on May 6-9, 2023."
Late-breaking abstract • Observational data
|
GUARDANT SHIELD
almost1year
Guardant Health Receives Medicare Coverage for Guardant360 Response to Monitor Cancer Patient Response to Immunotherapy (Businesswire)
"Guardant Health, Inc...announced today that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX), has conveyed coverage for the Guardant360 Response test....Following this decision, the Guardant360 Response test is now covered for fee-for-service Medicare patients in the U.S. with metastatic or inoperable solid tumors who are on an immune checkpoint inhibitor therapy. The coverage includes a Guardant360 CDx or LDT test before initiating therapy to establish a ctDNA baseline and a Guardant360 Response test 4 to 10 weeks after the therapy has been initiated to measure the change in ctDNA level."
Reimbursement
|
Guardant360 Response™
1year
Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting (Businesswire)
"Guardant Health, Inc...announced today that it will present data from 14 studies highlighting advances in precision oncology and cancer screening at the 2023 American Association for Cancer Research (AACR) Annual Meeting, April 14-19 in Orlando, Florida....In particular, studies show that: Methylome sequencing with a liquid-only approach using the GuardantINFINITY platform can quantify circulating tumor DNA level and change with greater sensitivity and precision than genomic sequencing, making longitudinal ctDNA monitoring accessible to a broader range of patients....The analytical validation of the GuardantINFINITY genomic and epigenomic liquid biopsy platform showed its potential for ultra-sensitive ctDNA detection for minimal residual disease and recurrence surveillance, tumor fraction quantitation for therapy monitoring, oncogenic virus detection, immunogenotyping, epigenotyping, and tumor phenotype characterization, representing a new standard in biomarker discovery."
Clinical data
|
Guardant360® CDx • GUARDANT SHIELD • GuardantINFINITY™
1year
Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence (Businesswire)
"Guardant Health, Inc...has announced support for an investigator initiated study led and conducted by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) to evaluate patient compliance with a blood-based test for colorectal cancer (CRC) screening. In this study, The Ohio State University Guardant Shield Colorectal Cancer Screening Project, individuals from minority and underserved populations aged 45 and older who are in need of CRC screening will have the option to receive the Shield blood test, administered by a mobile phlebotomist, as part of their engagement with a community health van."
Licensing / partnership
|
GUARDANT SHIELD
1year
Lunit wins 'CLIA certification' from Guardant Health (Korea Biomedical Review)
"Lunit said it has completed validation of Lunit Scope PD-L1, its artificial intelligence pathology analysis solution, in Clinical Laboratory Improvement Amendments (CLIA)'s laboratory-developed test (LDT)...The company conducted the test at Guardant Health's CLIA Lab."
Regulatory
|
Lunit SCOPE PD-L1
1year
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield blood test (Businesswire)
"Guardant Health, Inc...announced that it has submitted to the U.S. Food and Drug Administration (FDA) the final module of its premarket approval (PMA) application for Shield™, Guardant Health’s blood test to screen for colorectal cancer (CRC). The submission is comprised of data from the company’s positive ECLIPSE study, an over 20,000 patient registrational study evaluating the performance of its blood test for detecting colorectal cancer in average-risk adults."
FDA event
|
GUARDANT SHIELD
1year
Sermonix Pharma Using Guardant Health CDx to Screen Breast Cancer Patients for Lasofoxifene Trial (Precision Oncology News)
"Sermonix Pharmaceuticals is starting a Phase III trial of endocrine therapy lasofoxifene for patients with locally advanced or metastatic ER+/HER2-breast cancer with an estrogen receptor 1 (ESR1) mutation, the company said on Thursday. Sermonix has partnered with Guardant Health for the trial and will use the Guardant360 CDx liquid biopsy assay, a blood-based sequencing test that detects mutations from circulating tumor DNA, to determine eligibility by screening patients for ESR1 variants. The trial, dubbed the ELAINE-3 study, will compare lasofoxifene against fulvestrant, an estrogen receptor antagonist, both in combination with Eli Lilly's CDK4/6 inhibitor Verzenio (abemaciclib)....Sermonix expects to dose the first patient for the trial in the first half of this year and plans to enroll 400 patients in total."
Trial status • Licensing / partnership
|
Guardant360® CDx
|
Fablyn (lasofoxifene)
1year
Guardant Health initiates new study to examine the impact of Shield™ blood test to increase screening compliance for colorectal cancer (Guardant Health Press Release)
"Guardant Health, Inc...announced the initiation of a new study to examine patient preference for Shield, Guardant Health’s blood test to screen for colorectal cancer (CRC), and if having the option of a blood test improves patient adherence to screening. The study will be conducted by the Center for Asian Health Equity – University of Chicago Medicine (CAHE-UCM)."
New trial
|
GUARDANT SHIELD
1year
Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer (Guardant Health Press Release)
"Guardant Health, Inc...announced...UnitedHealthcare (UHC) now covers the Guardant360® CDx liquid biopsy test for patients enrolled in its commercial policies for all FDA-approved companion diagnostic indications...The new policy coverage by UnitedHealthcare is in addition to existing coverage of the Guardant360 CDx test under UHC Medicare Advantage policies for comprehensive genomic profiling of all solid tumors."
Medicare • Reimbursement
|
Guardant360® CDx
1year
Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360 CDx and Guardant360 TissueNext as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (Businesswire)
"Guardant Health Inc...announced today a strategic collaboration on the development, regulatory approval and commercialization of the Guardant360® CDx and Guardant360 TissueNext™ assays as companion diagnostics for taletrectinib in the United States and European Union....The collaboration will focus on the use of the Guardant tests for comprehensive genomic profiling to identify patients with the specific tumor mutations that are targeted by taletrectinib."
Licensing / partnership
|
Guardant360® CDx • Guardant360 TissueNext™
|
taletrectinib (AB-106)
1year
Guardant Health introduces Guardant Galaxy suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery (Businesswire)
"Guardant Health, Inc...announced today the introduction of Guardant GalaxyTM, a suite of advanced analytical technologies developed internally and through outside partnerships to enhance the performance and clinical utility of Guardant Health’s portfolio of cancer tests and to power the next generation of biomarker and drug discovery....The AI-powered scoring algorithm for the enhanced Guardant360 TissueNext PD-L1 test, which is now commercially available, improved detection of the cancer biomarker by more than 20 percent compared to manual pathologist interpretation in the most challenging non-small cell lung cancer (NSCLC) cases....Guardant Health also plans to expand the Guardant Galaxy technology suite over time to include other technology partnerships that will support additional segments of its cancer diagnostics portfolio."
Clinical
|
Guardant360 TissueNext™
1year
FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer (FDA)
"On January 27, 2023, the Food and Drug Administration (FDA) approved elacestrant (Orserdu, Stemline Therapeutics, Inc.) for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. FDA also approved the Guardant360 CDx assay as a companion diagnostic device to identify patients with breast cancer for treatment with elacestrant."
NDA • FDA event
|
Guardant360® CDx
|
Orserdu (elacestrant)
1year
Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal blood test to help guide treatment decisions in colorectal cancer (Guardant Health Press Release)
"Guardant Health, Inc...is partnering with The Royal Marsden NHS Foundation Trust on Part C of its 'Tracking mutations in cell free DNA to predict Relapse in eArly Colorectal Cancer' (TRACC) study, which will evaluate the use of circulating tumor DNA (ctDNA) to guide chemotherapy treatment decisions after curative-intent surgery in patients with early-stage colorectal cancer (CRC)...The trial is intended to determine whether patients can be spared unnecessary chemotherapy and the associated side effects if they test negative for ctDNA using the Guardant Reveal™ blood test following surgery."
Licensing / partnership
|
GuardantREVEAL
1year
Guardant Health to showcase new data at ASCO GI 2023 demonstrating utility of its blood tests for patients with gastrointestinal cancers (Guardant Health Press Release)
"Guardant Health, Inc...announced...that new data from its portfolio of blood tests will be presented at the ASCO 2023 Gastrointestinal Cancers Symposium, January 19-21 in San Francisco...The 10 poster presentations highlight the use of the Guardant360® and Guardant Reveal blood tests and the GuardantINFORM real-world evidence dataset to identify critical biomarkers and acquired co-mutations, track associated treatment patterns and clinical outcomes, and predict disease recurrence from minimal residual disease (MRD) detection."
Real-world evidence • Clinical data
|
Guardant360® CDx • GuardantREVEAL
over1year
Guardant Health and Susan G. Komen® partner to develop clinical studies to identify early-stage breast cancer patients who may benefit from additional monitoring or therapy (Guardant Health Press Release)
"Guardant Health, Inc...and Susan G. Komen®...announced...that they have entered into a partnership to bring the patient perspective to the development of clinical studies that help identify early-stage breast cancer patients who are at high risk of disease recurrence and may benefit from additional monitoring or therapy...The focus of the partnership will be to support the development of clinical utility data for Guardant Reveal™, a blood test for the detection of minimal residual disease (MRD) in patients with early-stage breast cancer."
Licensing / partnership
|
GuardantREVEAL